The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01283958

Enrollment

Registered

2011-01-26

Start date

2007-09-30

Completion date

2010-05-31

Last updated

2011-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eisenmenger's Syndrome

Keywords

Iloprost, Eisenmenger's syndrome

Brief summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Outcome results